Live
- Chanchalguda Jail Officials Say They Haven't Received Bail Papers Yet, Allu Arjun May Stay in Jail Tonight
- BJP leaders present evidence of illegal voters in Delhi, urge EC for swift action
- Exams will not be cancelled: BPSC chairman
- Nagesh Trophy: Karnataka, T.N win in Group A; Bihar, Rajasthan triumph in Group B
- YS Jagan condemns the arrest of Allu Arjun
- Economic and digital corridors to maritime connectivity, India and Italy building vision for future, says Italian Ambassador
- SMAT 2024: Patidar's heroics guide Madhya Pradesh to final after 13 years
- CCPA issues notices to 17 entities for violating direct selling rules
- Mamata expresses satisfaction over speedy conviction in minor girl rape-murder case
- Transparent Survey Process for Indiramma Housing Scheme Directed by District Collector
Natco to make Covid drug in pact with Eli Lilly
Natco to make Covid drug in pact with Eli Lilly
Drug firm Eli Lilly on Monday said it has signed a voluntary licensing agreement with Hyderabad-based company Natco Pharma to further expedite the availability of baricitinib for Covid-19 patients in India
New Delhi: Drug firm Eli Lilly on Monday said it has signed a voluntary licensing agreement with Hyderabad-based company Natco Pharma to further expedite the availability of baricitinib for Covid-19 patients in India.
The company has issued an additional royalty-free, non-exclusive voluntary license to Natco Pharma and the company will be collaborating with Eli Lilly to further accelerate and expand the availability of baricitinib in India during this pandemic.
The move will improve the local treatment options available and will positively impact the lives of people who are currently battling Covid-19 in India, Eli Lilly said in a statement.
Earlier, the company had announced signing of six voluntary license agreements with Cipla, Lupin, Sun Pharmaceutical Industries, Dr Reddy's, MSN Laboratories and Torrent Pharmaceuticals. Eli Lilly and Company has received permission for restricted emergency use by the Central Drugs Standard Control Organisation (CDSCO), for baricitinib to be used in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation, the statement said.
Meanwhile, Eli Lilly and Company said it continues to engage in active dialogue with the regulatory authorities and government in India to deliver baricitinib donations through the humanitarian aid organisation, Direct Relief, and to donate it's anti-Covid-19 treatments, including Lilly's neutralising antibodies.
